Medicilon Honors Revolution Medicines with Client Partnership Excellence Award
Medicilon, a leading provider of drug discovery services, recently celebrated its longstanding collaboration with Revolution Medicines by awarding them the prestigious "Excellence in Client Partnership Award." This event took place on October 30, 2026, in Boston, with Dr. Yang Liu, the medicinal chemistry director at Revolution Medicines, and Dr. Kristof Pota, a senior scientist, visiting Medicilon's R&D center in Nanhui. They were welcomed by Dr. Maosheng Duan, president of Medicilon’s drug discovery and pharmaceutical research divisions, and Dr. Jian Wang, vice president of Medicilon.
During their visit, both teams engaged in comprehensive discussions about ongoing projects, data transfer processes, and strategic priorities for the upcoming year. The award presented to Revolution Medicines acknowledges the significant clinical value brought about by the innovative development of pan-KRAS therapies, underlining years of mutual effort, trust, and shared success in their R&D endeavors.
The partnership, built over the last three years, has fostered a robust model of collaboration, with Medicilon's team working closely to tackle R&D challenges while maintaining a client-focused approach aimed at delivering high-quality molecules efficiently. Dr. Duan commended Revolution Medicines for its groundbreaking work in advancing KRAS therapies, previously deemed 'undruggable,' as well as for obtaining FDA approval in August 2026 for the NDA related to daraxonrasib for metastatic pancreatic cancer. This milestone brings new hope for pancreatic cancer patients and signifies a substantial clinical advance.
The award signifies more than acknowledgment; it reflects a deep trust and commitment developed through collaborative efforts over three years. As Medicilon and Revolution Medicines strive to deepen their partnership, comprehensive discussions focused on exploring new collaborative opportunities were held.
Dr. Wang detailed Medicilon’s growth and its integrated R&D platform, which spans from target discovery to IND submission. Medicilon's quality system meets international standards and carries several important certifications, including NMPA, OECD GLP, FDA GLP, and AAALAC. The company possesses advanced platforms supporting ADC/AOC programs, TPD, RIPTAC, RNAi, and peptides.
Conversations also included topics like inter-regional data transfer, project management, and the future of international collaboration, all focusing on enhancing R&D efficiency. Following these discussions, Dr. Liu and Dr. Pota toured Medicilon's R&D laboratories, including facilities for chemistry and oligonucleotides, as well as areas dedicated to API research and preclinical studies, providing them with a firsthand understanding of Medicilon's R&D infrastructure and quality management system.
Innovative partnerships like the one between Medicilon and Revolution Medicines exemplify the power of collaborative efforts in the pharmaceutical industry. As they continue to succeed together, these relationships are vital for bringing groundbreaking therapies to patients in need, giving hope for a better future in cancer treatment and beyond.
During their visit, both teams engaged in comprehensive discussions about ongoing projects, data transfer processes, and strategic priorities for the upcoming year. The award presented to Revolution Medicines acknowledges the significant clinical value brought about by the innovative development of pan-KRAS therapies, underlining years of mutual effort, trust, and shared success in their R&D endeavors.
The partnership, built over the last three years, has fostered a robust model of collaboration, with Medicilon's team working closely to tackle R&D challenges while maintaining a client-focused approach aimed at delivering high-quality molecules efficiently. Dr. Duan commended Revolution Medicines for its groundbreaking work in advancing KRAS therapies, previously deemed 'undruggable,' as well as for obtaining FDA approval in August 2026 for the NDA related to daraxonrasib for metastatic pancreatic cancer. This milestone brings new hope for pancreatic cancer patients and signifies a substantial clinical advance.
The award signifies more than acknowledgment; it reflects a deep trust and commitment developed through collaborative efforts over three years. As Medicilon and Revolution Medicines strive to deepen their partnership, comprehensive discussions focused on exploring new collaborative opportunities were held.
Dr. Wang detailed Medicilon’s growth and its integrated R&D platform, which spans from target discovery to IND submission. Medicilon's quality system meets international standards and carries several important certifications, including NMPA, OECD GLP, FDA GLP, and AAALAC. The company possesses advanced platforms supporting ADC/AOC programs, TPD, RIPTAC, RNAi, and peptides.
Conversations also included topics like inter-regional data transfer, project management, and the future of international collaboration, all focusing on enhancing R&D efficiency. Following these discussions, Dr. Liu and Dr. Pota toured Medicilon's R&D laboratories, including facilities for chemistry and oligonucleotides, as well as areas dedicated to API research and preclinical studies, providing them with a firsthand understanding of Medicilon's R&D infrastructure and quality management system.
Innovative partnerships like the one between Medicilon and Revolution Medicines exemplify the power of collaborative efforts in the pharmaceutical industry. As they continue to succeed together, these relationships are vital for bringing groundbreaking therapies to patients in need, giving hope for a better future in cancer treatment and beyond.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.